These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29668561)

  • 1. A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy.
    Abd-Elsalam S; El-Kalla F; Elwan N; Badawi R; Hawash N; Soliman S; Soliman S; Elkhalawany W; ElSawaf MA; Elfert A
    J Clin Gastroenterol; 2019 Mar; 53(3):226-230. PubMed ID: 29668561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
    Sharma P; Sharma BC; Agrawal A; Sarin SK
    J Gastroenterol Hepatol; 2012 Aug; 27(8):1329-35. PubMed ID: 22606978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
    Agrawal A; Sharma BC; Sharma P; Sarin SK
    Am J Gastroenterol; 2012 Jul; 107(7):1043-50. PubMed ID: 22710579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
    Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
    J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.
    Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS
    Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
    Rahimi RS; Singal AG; Cuthbert JA; Rockey DC
    JAMA Intern Med; 2014 Nov; 174(11):1727-33. PubMed ID: 25243839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial.
    Glal KAM; Abd-Elsalam SM; Mostafa TM
    J Hepatobiliary Pancreat Sci; 2021 Oct; 28(10):812-824. PubMed ID: 33768619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
    Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
    Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy.
    Sharma BC; Singh J; Srivastava S; Sangam A; Mantri AK; Trehanpati N; Sarin SK
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1234-1239. PubMed ID: 27885712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
    Sharma BC; Sharma P; Agrawal A; Sarin SK
    Gastroenterology; 2009 Sep; 137(3):885-91, 891.e1. PubMed ID: 19501587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
    Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
    Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA; Regal RE; Alaniz C
    Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of lactulose treatment on the course of subclinical hepatic encephalopathy].
    Zeng Z; Li YY
    Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1126-9. PubMed ID: 12921628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
    Sharma P; Sharma BC; Sarin SK
    Eur J Gastroenterol Hepatol; 2010 May; 22(5):526-31. PubMed ID: 20009938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.